CHIP et cancers de l’ovaire : pour quelles patientes ?

作者: Léonie Picard , Charlotte Bourgin , Frédérique Penault-Llorca , Marie Beguinot , Caroline Cornou

DOI: 10.1016/J.BULCAN.2019.04.003

关键词: Hyperthermic intraperitoneal chemotherapyInternal medicineOvarian carcinomaContext (language use)MedicinePeritoneal carcinomatosisOncologyOverall survivalFirst line

摘要: The results of PRODIGE 7 study demonstrate that the use HIPEC is not beneficial for patients in treatment colorectal carcinomatosis. Nevertheless, a recent published NewEnglandJournalofMedicine showed hyperthermic intraperitoneal chemotherapy (HIPEC) increased overall survival with ovarian peritoneal Although, emergence targeted therapies (anti-angiogenic agents, PARP-inhibitors, anti-PDL1) new standards first line or recurrence disease. In this general context, what potential interest carcinoma?

参考文章(41)
Annie Cortez, Coraline Dubot, Domnita Burcoveanu, Roman Rouzier, Frédéric Selle, Marc Bazot, Chimiothérapie des récidives des cancers de l’ovaire Médecine thérapeutique / Médecine de la reproduction, gynécologie et endocrinologie. ,vol. 14, pp. 51- 62 ,(2012) , 10.1684/MTE.2012.0415
Franco M. Muggia, Patricia S. Braly, Mark F. Brady, Gregory Sutton, Theodore H. Niemann, Samuel L. Lentz, Ronald D. Alvarez, Paul R. Kucera, James M. Small, Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study Journal of Clinical Oncology. ,vol. 18, pp. 106- 115 ,(2000) , 10.1200/JCO.2000.18.1.106
Kenneth Jaaback, Nick Johnson, Theresa A Lawrie, Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer Cochrane Database of Systematic Reviews. ,(2016) , 10.1002/14651858.CD005340.PUB4
N. Bakrin, J.M. Bereder, E. Decullier, J.M. Classe, S. Msika, G. Lorimier, K. Abboud, P. Meeus, G. Ferron, F. Quenet, F. Marchal, S. Gouy, P. Morice, C. Pomel, M. Pocard, F. Guyon, J. Porcheron, O. Glehen, Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patients. Ejso. ,vol. 39, pp. 1435- 1443 ,(2013) , 10.1016/J.EJSO.2013.09.030
C.S. Chia, W.J. Tan, J.F. Sze Wong, G.H. Ching Tan, C. Lim, W. Wang, E.I.-l. Sin, C.K. Tham, K.C. Soo, M.C.C. Teo, Quality of life in patients with peritoneal surface malignancies after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy Ejso. ,vol. 40, pp. 909- 916 ,(2014) , 10.1016/J.EJSO.2013.12.028
Maurie Markman, Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity Critical Reviews in Oncology/Hematology. ,vol. 14, pp. 15- 28 ,(1993) , 10.1016/1040-8428(93)90003-M
STEPHEN B. HOWELL, Intraperitoneal Cisplatin with Systemic Thiosulfate Protection Annals of Internal Medicine. ,vol. 97, pp. 845- 851 ,(1982) , 10.7326/0003-4819-97-6-845
Philipp Harter, Andreas du Bois, Maik Hahmann, Annette Hasenburg, Alexander Burges, Sibylle Loibl, Martina Gropp, Jens Huober, Daniel Fink, Willibald Schröder, Karsten Muenstedt, Barbara Schmalfeldt, Guenter Emons, Jacobus Pfisterer, Kerstin Wollschlaeger, Hans-Gerd Meerpohl, Georg-Peter Breitbach, Berno Tanner, Jalid Sehouli, Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial Annals of Surgical Oncology. ,vol. 13, pp. 1702- 1710 ,(2006) , 10.1245/S10434-006-9058-0
Eddy Cotte, Olivier Colomban, Jérome Guitton, Brigitte Tranchand, Nawel Bakrin, François‐Noël Gilly, Olivier Glehen, Michel Tod, None, Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure. The Journal of Clinical Pharmacology. ,vol. 51, pp. 9- 18 ,(2011) , 10.1177/0091270009360980